Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | Clinical implementations of AlzoSure Predict

Paul Kinnon, CEO, Diadem SpA, Brescia, Italy, evaluates how Diadem’s AlzoSure® Predict tool could influence Alzheimer’s disease (AD) clinical trials, drug development, and patient monitoring. AlzoSure® Predict uses an antibody to determine levels of an unfolded conformational variant of p53 known as U-p53AZ, thought to be involved in AD pathogenesis. U-p53AZ outperformed amyloid-PET imaging in predicting progression to AD, achieving an area under the curve of over 98% for identifying progression to symptomatic AD up to six years prior to diagnosis. The test would allow for the enrichment of AD clinical trials, particularly those which are investigating early course disease-modifying drugs. It is also of benefit to patients who would be able to receive a prognosis years before the onset of cognitive decline. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.